Clinical Trials · NCT05841238
A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 52
- Start date
- Apr 2023
- Locations
- 3 sites, United States
- Primary endpoint
- Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to the 24 Hour Time Point (AUC[0-24]) of LY3502970